FDA clears blood test that flags brain amyloid for Alzheimer’s diagnosis
TL;DR
The FDA has approved Roche’s blood test that detects brain amyloid, a biomarker for Alzheimer’s disease, to help diagnose suspected cases. It is not intended for routine screening and could be easier to administer in primary care than PET scans or cerebrospinal fluid tests, potentially enabling earlier, less invasive confirmation for patients and families.
Topics:businesshealth#alzheimers-disease#diagnostic-tests#health#medical-diagnostic-technology#medical-research#us-food-and-drug-administration
- FDA approves a new blood test to detect signs of Alzheimer’s The Washington Post
- Another Alzheimer’s blood test gets OK from FDA CNN
- FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly WSJ
- Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood test Fierce Biotech
- FDA approves new blood test for Alzheimer’s disease The Hill
Want the full story? Read the original reporting
Read on The Washington Post